Amgen Inc. (AMGN) Stock Price & How to Invest

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amgen Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$33-35 billion (approximate, verify)
• Operating margin: ~30%+ (approximate, verify)
• P/E (TTM): ~20-25x (GAAP varies; approximate, verify)
• Dividend yield: ~3% (approximate, verify)
• Market cap: ~$150 billion-plus (approximate, verify)
• Net debt: Elevated after the Horizon acquisition (verify)
• Index membership: Dow Jones Industrial Average, S&P 500, Nasdaq-100

Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

If you want AMGN exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses AMGN naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that show up alongside AMGN in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.

There are three common ways to get AMGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DIVO, SCHD, DIA), which spreads the position across many companies. Or build it into a focused thematic basket, so AMGN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where AMGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Amgen (AMGN) is a mature large-cap biopharma whose thesis rests on defending its biologics franchise, growing rare-disease and biosimilar revenue, and converting its pipeline (including obesity candidates) into new drugs. In a portfolio it behaves as a defensive, dividend-paying healthcare holding with patent-cliff and clinical-trial risk, rather than a high-growth position.

Whether AMGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMGN a buy?, and where the stock could go from here in the AMGN stock forecast.

For income investors, whether AMGN pays a dividend and how the payout looks is covered in does AMGN pay a dividend? And to weigh AMGN against a peer, read the full side-by-side comparisons: AMGN vs LLY and AMGN vs NVO.